Microsoft Corporation (NASDAQ MSFT) is suing Samsung for failure to fully pay all patent licensing fees relating to the Korean tech giant’s line of Android smartphones. Samsung only issued a very brief statement: “We will review the complaint in detail and determine appropriate measures in response.” Microsoft Corporation (NASDAQ MSFT) and Samsung have a long-standing…
Apple Inc (NASDAQ AAPL) has customer privacy on its priority list. The Cupertino tech giant recently made a decision to prevent developers from selling data stored in the HealthKit API to advertisers. These changes were made a part of the developers license agreement. Apple updates its agreement to prevent developers from selling information or data…
Advertisers can now target their ads based on signal strength on Facebook Inc (NASDAQ FB). Essentially, the announcement for Facebook will allow advertisers to limit their data-heavy ads like video to those using 4G connections and not waste their marketing dollars on people connecting to the social media site through 2G connections in remote locations…
Google Inc (NASDAQ GOOG) revealed yesterday that the company would no longer display authors names in search results because it doesn’t seem to affect which links people click on one way or the other. But what’s more surprising to people webmasters who deal with SEO on a regular basis is that authorship won’t be used…
Microsoft Corporation (NASDAQ MSFT) is heavily rumored to unveil the highly anticipated ‘selfie’ smartphone on September 4th during the IFA event in Berlin. The Lumia 730 has already been leaked since June. Microsoft reportedly plans to launch purporte selfie smartphone early next month at IFA trade show. Yesterday, the company sent a ‘save-the-date’ email asking…
In a move which can have a lasting impact in the biotech segment of the stocks market, Bristol-Myers Squibb Company (BMY) entered into a collaboration with Celgene Corporation (CELG) to asses the safety, tolerability and preliminary efficacy of a cocktail therapy including its high potential immuno-oncology drug Opdivo (nivolumab, a PD-1 immune checkpoint inhibitor) and…
